PD-1 and PD-L1 blockade as single treatment showed no antitumoral activity in vivo, while efficacy improved when it was combined with imatinib, by down-regulating IFN-γ-related genes and suppressing PD-L1 expression on tumor cells [7]. The gene discussed is CD274; the disease is neoplasm.